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Predicting mortality in HIV-infected children initiating highly active antiretroviral therapy: A risk 
scoring system for resource-limited settings 
 
Background:  Access to highly active antiretroviral therapy (HAART) among HIV-infected children in 
sub-Saharan Africa is increasing.  WHO estimated that 387,500 children were receiving HAART in this 
region at the end of 2010.  Recent studies have demonstrated that children starting HAART in resource-
poor countries can achieve similar outcomes to children in resource-rich countries.  However, mortality 
rates remain higher in resource-poor countries, especially during the first six months of therapy.  Despite 
scaled-up HAART programs, no prognostic models predicting risk of death are available for children 
initiating HAART in resource-limited settings.  Current clinical prediction tools for HIV-infected children 
are derived from pre-HAART data and therefore cannot predict mortality in children on HAART.  The 
purpose of this study was to develop a mortality risk scoring system for HAART-naïve, HIV-infected 
children beginning therapy in a resource-limited setting.  In addition, we have conducted a systematic 
review of the literature identifying the risk factors associated with early mortality and the causes of early 
death in children initiating HAART (Appendix). 
 
Methods:  Observational data were collected and analyzed from HIV-infected children initiating HAART 
between December 2004 and April 2012 at Kalembe Lembe Pediatric Hospital and Bomoi Health Care 
Center in Kinshasa, Democratic Republic of the Congo.  Univariate and adjusted Cox proportional 
hazards models were constructed to assess associations between demographic and clinical characteristics 
at the time of HAART initiation and mortality.  Each variable in the final Cox model received a predictor 
score.  Predictor scores were summed to obtain an overall risk score for each child beginning HAART.  
The risk scoring system was validated internally using bootstrap resampling techniques.  Performance of 
the final model was measured by Harrell’s C statistic.   
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Results:  By April 2012, 1005 children had initiated HAART with 3017.4 child-years of follow-up 
(median 30.8 months on HAART).  One hundred children (10.0%) died at a median of 5.3 months post-
HAART initiation, yielding a mortality rate of 3.3 deaths (95% CI: 2.7-4.0) per 100 child-years.  The final 
multivariable model included female gender, anemia, severe malnutrition, presence of HIV symptoms, 
low total lymphocyte count, and age greater than 5 years.  These determinants were highly predictive of 
mortality (C-statistic=0.81).  The discriminative ability of our model was comparable to existing pediatric 
AIDS survival scores that do not account for HAART (C-statistic=0.84). 
 
Conclusions:  Mortality risk among children starting HAART in this resource-limited setting can be 
evaluated using a simple scoring system incorporating several readily available factors.  Identifying 
significant predictors of mortality will help clinicians target modifiable risk factors, like anemia and 
malnutrition, not addressed by HAART.  External validation of this model within pediatric HIV-infected 
cohorts in other resource-limited settings is needed to confirm its utility in assessing prognosis. 
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Introduction 
 
 Human immunodeficiency virus (HIV) infection disproportionately affects children in the 
poorest parts of the world.  There are 3.4 million children living with HIV and more than 90% of 
these children live in sub-Saharan Africa.
1
  Highly active antiretroviral therapy (HAART) has 
reduced mortality substantially, with 90% of adults and children alive one year following 
HAART initiation. 2-4  While untreated adults survive an average of 10 years after 
seroconversion,
5,6
 more than half of untreated infants die by two years of age.
6-9
  Yet only 23% 
of therapy-indicated children are currently receiving HAART, compared to 51% of adults.
1
  
 Nevertheless, access to HAART for HIV-infected children is increasing, which is vital as 
diagnostics improve and treatment guidelines expand.
10-13
  The World Health Organization 
(WHO) estimated that 456,000 children were receiving HAART in low- and middle-income 
countries at the end of 2010, compared to 127,000 in 2006.
1
  Recent studies have demonstrated 
that children starting HAART in resource-poor countries can achieve similar outcomes to 
children in resource-rich countries.
14,15
  However, mortality remains higher in resource-poor 
countries, especially during the first six months of treatment.
16,17
  Despite scaled-up HAART 
programs, no prognostic models predicting risk of death are available for children initiating 
HAART in resource-limited settings.  Current clinical prediction tools for HIV-infected children 
are derived from pre-HAART data and therefore cannot predict mortality in children on 
HAART.
18,19
   
 The purpose of this study was to develop a mortality risk scoring system for HAART-
naïve, HIV-infected children beginning therapy in a resource-limited setting.  Identifying 
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significant predictors of mortality will help clinicians target modifiable risk factors that are not 
addressed by HAART. 
 
Methods 
 
  Study population.     The source of data for this study was a comprehensive HIV care and 
treatment program serving children and family members at Kalembe Lembe Pediatric Hospital 
and Bomoi Health Care Center in Kinshasa, Democratic Republic of the Congo (DRC).  Clinical 
and laboratory follow-up, cotrimoxazole prophylaxis, treatment of opportunistic and common 
infections, psychosocial support, and HAART were provided free of charge to the children.  The 
population for this analysis was the HIV-infected, HAART-naïve children who started HAART 
between December 2004 and April 2012. 
 
  Procedures.     At the initial HIV care visit, data were collected on age, weight, height, WHO 
clinical stage, CD4 cell count and percentage, hemoglobin, and commonly diagnosed 
opportunistic infections.  The decision to initiate HAART was made at each clinic visit based on 
physician assessment and both national and WHO guidelines.
10-13
  The parents or guardians of 
HAART-eligible children were counseled for adherence; HAART was initiated as soon as one 
week after the visit in which the child became eligible, and children were followed monthly or 
when they required medical attention.  Children not yet eligible for HAART were reassessed at 
three month intervals or when in need of medical attention.  HIV infection was confirmed by 
serological testing, with HIV viral load or DNA PCR in infants under 18 months of age.     
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 CD4 percentage and count were measured at the enrollment visit and every six months 
thereafter at the DRC National AIDS Reference Laboratory.  Viral load was not routinely 
assessed because of infrequent availability of the assay.  Standard first-line treatment was triple 
therapy consisting of zidovudine (AZT) or stavudine (d4T), lamivudine (3TC), and nevirapine 
(NVP) or efavirenz (EFV).  Single drug substitutions in case of toxicity included d4T for AZT or 
AZT for d4T, 3TC for abacavir (ABC) or ABC for 3TC, and NVP for EFV/nelfinavir (NLF) or 
EFV/NLF for NVP.  Children who withdrew from care or could not be located by three tracking 
attempts after a missed visit were classified as lost to follow-up.  Children who were lost to 
follow-up were censored at the date of last clinic visit.  
 All parents or guardians of children signed informed consent for participation.  Children 
older than 12 years of age assented and children older than 8 years of age received an 
information sheet about the study before enrollment.  The data analysis was approved by the 
Institutional Review Board of the University of North Carolina at Chapel Hill. 
 
  Statistical analysis.     Total time of follow-up was calculated using the date of the last 
registered clinic visit.  Time to mortality was assessed for subjects from the date of HAART 
initiation to the date of death.  Mortality rates overall, at 90 days of therapy (including day 90), 
and after 90 days of therapy were calculated with 95% confidence intervals.  These time points 
are consistent with prior convention.
20
 
 Cox proportional hazards models were constructed to assess associations between 
mortality and demographic and clinical characteristics at time of HAART initiation.  Children 
who were alive on 31 March 2012 were right-censored for the survival functions and Cox 
proportional hazards models estimating the hazard of overall mortality.  Children who were alive 
7 
 
at the three month visit after initiating HAART were right-censored in the 90-day mortality 
model.  Survival functions were estimated using the Kaplan-Meier product-limit method and 
survival function homogeneity was assessed using the log-rank test.   
 Associations between mortality and 11 covariates thought to be important correlates of 
mortality after HAART initiation were identified using Cox proportional hazards regression 
(Table 3).  Hemoglobin, severity of immunodeficiency, and total lymphocyte count (TLC) were 
recorded from the most recent laboratory visit prior to the start of HAART.  Hemoglobin was 
dichotomized at a cut-off value of 9 g/dl, below which children in low-income countries are 
considered to have significant iron deficiency anemia.
21
  Severity of immunodeficiency was 
calculated according to WHO guidelines using CD4 count or percentage and age at HAART 
initiation.
10
  TLC was collapsed into 2 categories  (<1200 cells/µl and ≥1200 cells/µl) because 
TLC less than 1200 cells/µl is considered a good predictor of disease severity in the absence of 
CD4 count.
22
  Age was stratified into 3 categories (<2 years, 2-5 years, ≥5 years) to reflect 
current WHO treatment guidelines.
13
  Weight-for-age z-score (WAZ) and height-for-age z-score 
(HAZ) at HAART initiation were calculated using 1978 National Center for Health Statistics 
standards, as these standards gave the most consistent results throughout all age groups in 
comparison to the 2000 Centers for Disease Control standards.
23
  Malnutrition was defined as 
WAZ less than -2 standard deviations (SDs) below the median and severe malnutrition as WAZ 
less than -3 SDs.
20,23
  Stunting and severe stunting were defined as HAZ less than -2 SDs and 
less than -3 SDs, respectively.
24
  HIV-related symptoms or conditions included one or more of 
the following: Kaposi’s sarcoma, oral or esophageal candidiasis, severe weight loss, tuberculosis, 
fever or diarrhea lasting one month or more, lymphocytic interstitial or Pneumocystis jirovecii 
pneumonia, chronic herpes simplex, oral hairy leukoplakia, cryptococcal meningitis, toxoplasma 
8 
 
or HIV encephalopathy, or HIV-associated nephropathy.
15
  HIV-related symptoms were 
considered present if recorded within one month of HAART initiation.  Each variable was 
represented using indicators with the least severe level as the referent category.  The 
characteristics of children between each age group were compared using the chi-squared test for 
proportions and the Kruskal-Wallis and Wilcoxon Rank-Sum tests for median CD4 counts and 
percentages (Table 1).  Differences between age groups were considered significant at p<0.05. 
Unadjusted hazard ratios (HRs) were calculated using simple Cox proportional hazards 
models for each variable.  All variables were included in the original multivariable Cox 
proportional hazards model.  The final multivariable model was fit using backward selection to 
eliminate non-significant variables at p<0.10.  The proportional hazards assumption was tested 
by examining Schoenfeld residuals for each variable in the final model in order to identify any 
independent variables significantly correlated with death event times.
25
  In multivariable 
analysis, only subjects with complete data were included.  In univariate analysis, subjects were 
included if they had complete data for the covariate of interest.  No data were imputed. 
 
  Scoring system.     To develop the clinical prediction rule, each variable in the multivariable 
Cox proportional hazards model received a predictor score.  As in prior published convention, 
HRs with a magnitude greater than or equal to 1 and less than 4 received a score of 1 point, HRs 
greater than or equal to 4 and less than 6 received a score of 2 points, and HRs greater than or 
equal to 6 received a score of 3 points.
18,19
  Referent categories received a score of 0 points.  
Predictor scores were summed to obtain an overall mortality risk score for each child beginning 
HAART.  Kaplan-Meier curves were stratified by total risk score to examine survival among 
patients with different scores.  The model was validated internally by bootstrap resampling 
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techniques using 250 resamples with replacement.
26
  Bootstrap-corrected 95% CIs were 
calculated for each variable included in the final model.  Performance of the model was 
measured by Harrell’s C statistic.27  A C statistic of 0.5 indicates that the model has no ability to 
discriminate between children who lived and children who died, while a C statistic of 1.0 
indicates that the model has perfect discriminative ability.  Statistical analyses were conducted 
using StataSE 12.0 software (StataCorp LP, College Station, TX). 
 
Results 
 
  Characteristics of children on HAART.     By April 2012, 1005 children had initiated HAART 
with 3017.4 child-years of follow-up on HAART.  Demographic and clinical characteristics of 
these children are described in Table 1.  At HAART initiation, 544 children (54.1%) were 
malnourished, and 242 (24.1%) were severely malnourished.  The median CD4 percentage was 
13% [interquartile range (IQR): 7-19%] and the median CD4 count was 449 cells/µl (IQR: 171-
871).  Children older than five years had lower CD4 counts and percentages than the other age 
groups.  At the start of HAART, 988 children (98.3%) received first-line therapy.  Fifteen 
children (1.5%) started on second-line therapy consisting of d4T/3TC/NLF, ABC/didanosine 
(ddI)/NLF, AZT/ddI/NLF, or a lopinavir/ritonavir-based regimen (ABC/ddI/LPV/r).  At the date 
of HAART initiation, 986 children (98.1%) were receiving cotrimoxazole (CTX) prophylaxis, 
including those children who started CTX and HAART on the same day. 
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  Mortality.     Median follow-up time on HAART was 30.8 months (IQR: 11.8-58.4).  One 
hundred children (10.0%) died at a median of 5.3 months (IQR: 1.0-21.8) post-HAART 
initiation, yielding an overall mortality rate of 3.3 deaths per 100 child-years (95% CI: 2.7-4.0) 
(Table 2).  Forty-three of the 100 deaths occurred within 90 days of HAART initiation (mortality 
rate in the first 90 days of HAART: 18.1 deaths per 100 child-years; 95% CI: 13.4-24.4) and 51 
deaths occurred within 6 months of HAART initiation.  The mortality rate after 90 days of 
HAART was 2.1 deaths per 100 child-years (95% CI: 1.6-2.7).  Children older than five years 
had the highest overall [3.7 deaths per 100 child-years (95% CI: 2.9-4.7)] and 90-day [22.7 
deaths per 100 child-years (95% CI: 15.8-32.6)] mortality rates.  Of the 1005 children initiating 
HAART, 113 (11.2%) were lost to follow-up, 4 (0.4%) transferred care to another clinic, 17 
(1.7%) voluntarily withdrew from the study, and 6 (0.6%) were deactivated for poor adherence. 
 
No. Value No. Value No. Value No. Value
Age, median (IQR), mos 1005 67.0 (26.9-121.3) 217 12.5 (8.2-18.8) 248 40.1 (30.7-50.2) 540 116.7 (85.2-147.7)
Female, % 347 34.5 67 30.9 75 30.2 205 38.0 a
Weight for age z-score, median (IQR) 1001  -2.2 (-3.0 to  -1.2) 216  -2.7 (-3.7 to -1.3) 247  -2.1 (-3.2 to -1.3) 538  -2.1 (-2.7 to -1.2)
       z < -3 b 242 24.2 87 40.3 71 28.7 84 15.6
       -3 ≤ z < -2 302 30.2 50 23.1 62 25.1 190 35.3 c
       z ≥ -2 457 45.7 79 36.6 d 114 46.2 264 49.1
CD4 cell percentage, median (IQR) e 864 13 (7-19) 188 17 (12-24) 221 14 (9-18) 455 11 (5-18)
       < Age-specific threshold for 
       severe immunodeficiency
570 66.0 121 64.4 146 66.1 303 66.6
CD4 cell count, median (IQR), cells/µl f 871 449 (171-871) 161 1052 (667-1682) 219 667 (359-979) 491 263 (87-531)
       < Age-specific threshold for 
       severe immunodeficiency
380 43.6 68 42.2 76 34.7 g 236 48.1
Hemoglobin, median (IQR), g/dl 886 10.2 (9.2-10.9) 157 9.9 (8.9-10.7) 221 10.2 (9.2-11.1) 508 10.2 (9.2-11.0) 
       < 9 g/dl 193 21.8 40 25.5 47 21.3 106 20.9
History of tuberculosis coinfection, % 460 45.8 81 37.3 h 123 49.6 256 47.4
WHO stage 3 or 4, % 606 60.5 131 60.6 155 62.8 320 59.4
First-line initial HAART regimen, % 988 98.3 205 95.3 i 248 100.0 535 99.1
Table 1.  Characteristics of children started on HAART according to age groups, Kinshasa, DRC (December 2004-April 2012)
a Significantly different from proportion of children 24-59 months
b Proportion of children in each age group is significantly different
c,d,h,i Significantly different from proportion of children in other age groups
g Significantly different from proportion of children ≥60 months 
         All Ages     Age < 2 yrs    Age 2-5 yrs     Age ≥ 5 yrs
Characteristic
e,f Median value in each age group is significantly different
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  Univariate assessment of mortality risk.     Univariate associations between demographic and 
clinical characteristics and both 90-day and overall mortality are shown in Table 3.  HIV-related 
symptoms, anemia, CD4 count below the threshold for severe immunodeficiency, CD4 percent 
below the threshold for severe immunodeficiency, severe malnutrition, severe stunting, WHO 
clinical stage 3 or 4, and low TLC were significantly associated with both 90-day and overall 
mortality.  Age and gender were not significantly associated with mortality in the univariate 
analysis.   
 
  Multivariable assessment of mortality risk.     In multivariable analysis, female gender 
(p=0.083), HIV-related symptoms (p=0.002), anemia (p=0.042), age more than five years 
(p=0.002), severe malnutrition (p<0.001), and low TLC (p<0.001) were associated with overall 
mortality at a significance level of p<0.10 (Table 3).  In the 90-day mortality model, presence of 
HIV-related symptoms was no longer associated with mortality after adjusting for other risk 
factors.  WHO clinical stage 3 or 4 (p=0.0102) was significantly associated with 90-day 
mortality in the multivariable model.   
No. Deaths
Follow-up, 
child-years
Mortality rate 
per 100 child-years 
    (95%CI)
All children
       Overall 999 a 100 3017.4 3.3 (2.7-4.0)
       Within 90 d 999 43 237.8 18.1 (13.4-24.4)
       After 90 d 910 57 2779.6 2.1 (1.6-2.7)
Children aged <2 yrs
       Overall 216 18 525.6 3.4 (2.2-5.4)
       Within 90 d 216 7 51.0 13.7 (6.5-28.8)
       After 90 d 192 11 474.6 2.3 (1.3-4.2)
Children aged 2-5 yrs
       Overall 246 17 737.7 2.3 (1.4-3.7)
       Within 90 d 246 7 58.9 11.9 (5.7-24.9)
       After 90 d 225 10 678.8 1.5 (0.8-2.7)
Children aged ≥5 yrs
       Overall 537 65 1754.1 3.7 (2.9-4.7)
       Within 90 d 537 29 127.9 22.7 (15.8-32.6)
       After 90 d 493 36 1626.2 2.2 (1.6-3.1)
a Six children were censored on the date of HAART initiation and therefore contributed 0 child-time
Table 2.  Mortality in children receiving HAART, Kinshasa, DRC (December 2004-April 2012) 
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  Derivation of scoring system.     The six determinants associated with overall mortality in the 
final Cox proportional hazards model were used to create the mortality risk scoring system.  For 
each variable in the final Cox proportional hazards model, the HR received a mortality risk score 
(Table 4).  Female gender, age≥5 years, presence of HIV-related symptoms or conditions, severe 
anemia, and severe malnutrition were scored as 1.  Low TLC was scored as 2.  Each child 
initiating HAART was assigned a total risk score based on the individual’s risk factor profile.  
By this method, a male child initiating HAART at age 10 months with a WAZ of -3.5, a 
hemoglobin of 8 g/dl, a TLC of 2000 cells/µl, and no HIV-related symptoms within the last 
month would have a score of 2: 0 (male) + 0 (age<5 years) + 1 (WAZ<-3) + 1 (hemoglobin<9 
g/dl) + 0 (TLC ≥1200 cells/µl) = 2.  This total score distinguished children with a poorer 
prognosis, as reflected by the Kaplan-Meier survival curves for the higher risk scores compared 
to those for the lower risk scores plotted in Figure 1.  The median total score at the start of 
Univariate HR
    (95% CI)
p value
Multivariate HR
    (95% CI)
p value
Univariate HR
    (95% CI)
p value
Multivariable HR
    (95% CI)
p value
Age group
       <2 yrs 217
       2-5 yrs 248 0.9 (0.3-2.5) 0.796 0.7 (0.4-1.5) 0.394
       ≥5 yrs 540 1.7 (0.7-3.8) 0.228 3.1 (1.4-7.3) 0.007 1.3 (0.7-2.1) 0.390 3.2 (1.5-6.6) 0.002
Gender
       Male 658
       Female 347 1.6 (0.9-3.0) 0.109 2.1 (1.1-4.2) 0.028 1.1 (0.8-1.7) 0.570 1.7 (0.9-3.1) 0.083
HIV symptoms or conditions
       Symptoms present 218 2.2 (1.0-5.0) 0.048 2.7 (1.7-4.4) <0.001 2.5 (1.4-4.6) 0.002
       Symptoms absent 408
WHO clinical stage
       Stage 1 or 2 396
       Stage 3 or 4 606 5.1 (2.0-13.0) 0.001 4.6 (1.4-15.4) 0.012 2.2 (1.4-3.5) 0.001
CD4 cell count
       Above threshold 491
       Below threshold (for severe immunodeficiency) 380 2.4 (1.2-4.7) 0.013 3.3 (2.1-5.3) <0.001
CD4 cell percentage
       Above threshold 294
       Below threshold (for severe immunodeficiency) 570 2.6 (1.1-6.3) 0.031 2.1 (1.2-3.6) 0.007
History of tuberculosis
       Present 460 1.5 (0.8-2.7) 0.195 1.3 (0.9-1.9) 0.232
       Absent 545
Hemoglobin
       <9 g/dl 193 2.0 (1.0-3.9) 0.046 1.4 (0.7-2.8) 0.400 1.7 (1.1-2.7) 0.018 1.9 (1.0-3.4) 0.042
       ≥9 g/dl 693
Weight for age z-score
       <-3 242 5.6 (3.0-10.5) <0.001 6.4 (3.1-13.2) <0.001 3.4 (2.3-5.0) <0.001 3.4 (1.8-6.5) <0.001
       ≥-3 759
Height for age z-score
       <-3 252 2.7 (1.5-5.0) 0.001 1.6 (1.1-2.5) 0.022
       ≥-3 748
Total lymphocyte count
       <1200 cells/µl 74 5.8 (3.0-11.5) <0.001 4.3 (2.1-8.8) <0.001 5.1 (3.1-8.4) <0.001 4.3 (2.2-8.4) <0.001
       ≥1200 cells/µl 707
Table 3.  Factors associated with 90-day and overall mortality in children starting HAART, Kinshasa, DRC (December 2004-April 2012)
Characteristic No.
90-day mortality Overall mortality
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HAART was 2 (IQR: 1-3).  In a Cox proportional hazards model in which the total score was 
fitted as a continuous covariate, there was a 132% (95% CI: 89%-185%) increase in mortality 
risk per one unit increase in total score. The final model had good discriminative ability, with a C 
statistic of 0.81.     
 
 
Figure 1.  Kaplan-Meier survival plot of the mortality risk scoring system including gender, presence of HIV-
related symptoms, age≥5 years, severe anemia, severe malnutrition, and low TLC within the study population 
(n=1005). 
Multivariate HR Mortality risk score
Age group
       ≥5 yrs 3.2 1
Gender
       Female 1.7 1
HIV symptoms or conditions
       Symptoms present 2.5 1
Hemoglobin
       <9 g/dl 1.9 1
Weight for age z-score
       <-3 3.4 1
Total lymphocyte count
       <1200 cells/µl 4.3 2
Table 4.  Mortality risk scoring system for children initiating HAART, 
Kinshasa, DRC (December 2004-April 2012)
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Discussion 
 
 Increasing access to HAART for HIV-infected children in sub-Saharan Africa requires 
that clinicians be able to predict prognosis in children beginning therapy.  Since mortality rates 
are highest within the first 90 days of initiating HAART, it is critical that clinicians identify risk 
factors associated with early mortality.  Our study describes factors that place children at 
increased risk for early mortality and develops a scoring system to assess overall prognosis in 
children with multiple risk factors.   
We found that female gender, severe malnutrition, low TLC, severe anemia, and age 
greater than five years were significantly associated with mortality, both overall and during the 
first 90 days of HAART.  The presence of HIV-related symptoms was significantly associated 
with overall mortality, while WHO clinical stage was a significant predictor of early mortality.  
Our results are consistent with previous studies in African pediatric cohorts showing that female 
gender, HIV symptoms, low weight-for-age z-score, WHO clinical stage, anemia, and low TLC 
are strongly associated with mortality after HAART initiation.
8,23,28-34
  
 One interesting finding from our study was the increased risk of mortality in children 
older than five years after controlling for other risk factors.  At the time of HAART initiation, 
children in this age group had significantly lower CD4 counts and percentages.  Severity of 
immunodeficiency, which accounts for age-related differences in CD4 values, was greater in this 
age group but not significantly greater.  In contrast, several studies of HIV-infected children in 
sub-Saharan Africa have found that age less than three years is significantly associated with 
mortality.
20,28,34,35
  As in our study, in which 53.7% of children were in the oldest age group, 
most children in sub-Saharan Africa are older than 5 years when they initiate HAART.
13
  By the 
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age of five years, 62-89% of untreated, HIV-infected children have died in other African 
cohorts.
9,36,37
  Children who survive beyond five years without HAART may have slower disease 
progression on HAART, resulting in lower mortality rates in this age group.  
Our study, however, found age over five years at the start of HAART to be significantly 
associated with mortality.  Delayed HIV diagnosis may contribute to the increased mortality rate 
in this age group.  Antibody-based assays for HIV diagnosis perform poorly in infants and 
virological assays were not yet widely available at the start of our study.
38
  Therefore, HIV-
exposed children often enter treatment programs at older ages in sub-Saharan Africa when they 
are presenting with advanced disease.  In our study, children in the oldest age group had the 
lowest median CD4 percent (11%) and CD4 count (263 cells/µl), placing them at increased risk 
for poor immunologic response on HAART.
39
  Three cohort studies in developed countries have 
observed that younger children initiating HAART are more likely to experience longer-term and 
faster increases in CD4 percent.
40-42
  The increased mortality risk seen in younger children in 
other resource-limited settings suggests that these children may not be achieving the same 
immunological response on HAART.
3,20,28,34,35
  Older children are more likely to experience 
virological failure and drug resistance on HAART.
43-45
  Improved understanding of mortality risk 
factors in older children on HAART is needed as more perinatally-infected children survive into 
adolescence, a time period when HIV-infected patients are often non-adherent.
45,46
 
We observed high early mortality in this resource-limited setting (mortality rate during 
the first 90 days of HAART: 18.1 deaths per 100 child-years), consistent with prior studies.
15,20,23
  
Early mortality rates on HAART differ between resource-rich and resource-poor countries.  In a 
meta-analysis using adult data, the adjusted HR of mortality comparing low-income to high-
income settings fell from 4.3 during the first month of treatment to 1.5 during months 7-12.
47
  A 
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large cohort study comparing South African and Swiss patients initiating HAART found adjusted 
HRs of mortality of 5.90 during months 1-3 and 1.77 during months 4-24, reflecting the higher 
background mortality in South Africa.
48
  Comorbidities left untreated in resource-poor countries, 
including invasive bacterial, mycobacterial, or fungal infections, may contribute to increased 
mortality in these settings.  Immune reconstitution inflammatory syndrome (IRIS), estimated to 
occur in 11.5 to 19.0% of children initiating HAART, is another possible factor.
49-51
  Children in 
resource-poor settings are at particularly high risk for IRIS because of the increased prevalence 
of IRIS-associated infections in these areas.  Pediatric HAART programs in low-resource 
settings also face structural challenges such as inadequate access to safe water, food, and quality 
health care, funding shortages, and interrupted supply chains for HIV drugs and diagnostics.
1,13,23
 
Prognostic models for children starting HAART must account for these disparities 
between resource-rich and resource-limited countries, as older age and increased disease severity 
at the time of HAART initiation in sub-Saharan Africa prevent direct comparison with children 
in resource-rich countries.  The Pediatric AIDS Severity Score (PASS) is a severity staging 
system that predicts mortality in HIV-infected children using baseline CD4 percentage, Centers 
for Disease Control and Prevention disease category, body mass index, neuropsychological 
score, general health rating, and symptoms score.
19
  The Simple PASS uses alternatives to CD4 
percentage and HIV RNA levels to predict mortality in resource-limited settings where these 
laboratory values may not be available.
18
  However, the Simple PASS was developed in a U.S.-
based cohort of HIV-infected children and therefore has limited generalizability to sub-Saharan 
Africa.  In addition, PASS was derived from a prospective cohort study including only those 
children enrolled prior to the use of HAART (pre-1996).
52
  With increasing availability of 
HAART in sub-Saharan Africa and the WHO guidelines now recommending HAART in all 
17 
 
children less than two years of age irrespective of disease status,
13
 a risk scoring system is 
needed to predict mortality in children initiating HAART. 
Our mortality risk score was highly predictive of mortality, with a C statistic of 0.81.  
The discriminative ability of our model was comparable to PASS (C statistic=0.84).  This 
scoring system can be used by clinicians to assess a child’s risk of death after HAART initiation 
based on clinical history and simple laboratory assays.  Identifying predictors of mortality may 
also help clinicians target modifiable risk factors, like anemia and malnutrition, that are only 
partially addressed by HAART.
53-59
  External validation of this model within pediatric HIV-
infected cohorts in other resource-limited settings is needed to confirm its utility in assessing 
prognosis.   
Our study has several limitations.  HIV-related symptoms data were absent for patients 
initiating HAART after 2010.  Data for hemoglobin, TLC, CD4 count, and CD4 percentage were 
also missing for many patients.  WHO clinical stage was recorded at each clinic visit but often 
evaluated in detail only at the initial enrollment visit.  Nevertheless, this complete case analysis 
describes predictors of mortality in a large cohort of HIV-infected children in sub-Saharan 
Africa.  It is possible that some of the 113 children (11.2%) lost to follow-up may have died, as 
seen in other African pediatric cohorts.
29,30
  However, active tracking of children who missed 
appointments decreased the likelihood that children who were classified as lost to follow-up had 
actually died.  The high mortality rate during the first 90 days of HAART (18.1 per 100 child-
years, 95% CI: 13.4-24.4) and the comparatively lower rate of loss to follow-up (5.5 per 100 
child-years, 95% CI: 3.2-9.4) during this high risk time period suggest that these children were 
correctly classified.  
18 
 
In conclusion, mortality risk among children starting HAART in this resource-limited 
setting can be evaluated using a simple scoring system incorporating several readily available 
factors.  As more HIV-infected children are now eligible for HAART at the outset of care and 
treatment programs continue to scale up, this scoring system, following external validation, can 
help clinicians predict prognosis and counsel patients and families about expected outcomes and 
modifiable risk factors.   
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Appendix 
Early mortality in HIV-infected children initiating highly active antiretroviral treatment in 
resource-poor settings: A systematic review 
 
Introduction 
 
 Most deaths in HIV-infected children on highly active antiretroviral therapy (HAART) 
occur within the first 90 days of initiating treatment.
2,15,20,23,28,32,34
  Observational studies of HIV-
infected children beginning HAART have found that 37 to 99 percent of all deaths occur during 
the first 90 days of treatment.
32,60
  Several pediatric cohort studies have assessed predictors of 
overall mortality in HIV-infected children beginning antiretroviral therapy.
3,8,23,28-34
  However, 
predictors of early mortality within the first three months of HAART initiation have been 
insufficiently documented in these children. 
 More than 90 percent of the 1200 new pediatric HIV infections each day occur in 
resource-limited settings.
13
  Yet only 23 percent of children in need of therapy are currently 
receiving it.
1
  Disparities persist among children receiving treatment.  HIV-infected children on 
ART in resource-poor countries suffer higher mortality rates than children in resource-rich 
countries, especially during the first three months of treatment.
47,48,61
   
Higher mortality in resource-poor countries can be partly explained by lower initial CD4 
counts and more advanced clinical stage.  Immune reconstitution inflammatory syndrome (IRIS), 
estimated to occur in 11.5 to 19.0 percent of children initiating HAART, may also contribute to 
the increased mortality risk in these areas.
49-51
  Children in resource-poor settings are at 
particularly high risk for IRIS because of the increased prevalence of IRIS-associated infections.  
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However, limited reporting on cause-of-death has prevented IRIS from being accurately 
quantified in these populations.   
 Given the disproportionate early mortality burden carried by children in resource-limited 
settings and the potential contribution of IRIS to these early deaths, a systematic review of the 
literature is needed to better define the risk factors associated with mortality during the critical 
90-day period following ART initiation.  Current efforts to develop a clinical prediction rule 
identifying those children who are at highest risk for early mortality after starting HAART will 
benefit from such a review.  In order to evaluate the role of IRIS in these early deaths, we need to 
determine which deaths might be associated with immune reconstitution.  Therefore, a 
systematic review is also needed to describe reporting of causes of death within the first 90 days 
of HAART initiation.  This systematic review seeks to answer two key questions (KQ): (1) What 
are the risk factors associated with mortality in HAART-naïve, HIV-infected children during the 
first 90 days after HAART initiation in resource-poor settings? (2) What are the causes of death 
among HAART-naïve, HIV-infected children who die within the first 90 days of initiating 
HAART in resource-poor settings?  
 
Methods 
 
Data Sources and Selection 
 We searched the MEDLINE® database from inception to 1 February 2012 using Medical 
Subject Headings (MeSH) as search terms with the full search strategy presented below in Figure 
1.  We limited electronic searches to “human” and “English language.”  We manually searched 
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reference lists of pertinent narrative reviews and studies on this topic to look for any relevant 
citations that might have been missed by our database searches.   
 
Search Most Recent Queries Result 
#1 Search “HIV Infections/mortality” 
[Mesh] 
5926 
#2 Search “Acquired Immunodeficiency 
Syndrome/mortality” [Mesh] 
2509 
#3 Search #1 OR #2 5926 
#4 Search “Antiretroviral Therapy, Highly 
Active” [Mesh] 
13960 
#5 Search “Anti-Retroviral Agents” [Mesh] 42756 
#6 Search #4 OR #5 50864 
#7 Search #3 AND #6 1790 
#8 Search “Child” [Mesh] 1413325 
#9 Search “Pediatrics” [Mesh] 39145 
#10 Search “Adolescent” [Mesh] 1443426 
#11 Search “Infant” [Mesh] 864399 
#12 Search #8 OR #9 OR #10 OR #11 2613987 
#13 Search #7 AND #12 467 
Figure 1.  Search strategy for MEDLINE using MeSH terms as available. 
 
Study Selection 
 We reviewed cohort studies conducted in resource-poor settings that examined the effect 
of HAART on mortality in HIV-infected, HAART-naïve children or assessed predictors of 
mortality in these children.  We developed eligibility criteria (inclusion and exclusion criteria) 
with respect to patient populations, interventions, comparisons, outcomes, settings, study 
designs, and durations for the two key questions. 
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Eligibility Criteria 
Population:                       Participants are HAART-naïve, HIV-infected children, aged 0 to 18   
                                           years, initiating HAART in resource-limited settings. 
Intervention/Exposure:  Assesses baseline mortality risk factors in HIV-infected children   
                                           initiating HAART.  
Comparator:                    HAART-naïve, HIV-infected children beginning HAART in the resource-             
                                           limited setting who do not possess the risk factor of interest.   
Outcomes:                        KQ 1:  The primary outcome is mortality within the first 90 days of  
                                           initiating HAART and the study must describe or quantify the risk or  
                                           hazard of mortality within the first 90 days on HAART given the presence of  
                                           each risk factor. 
                                           KQ 2:  The study reports causes of death for deaths occurring within  
                                           90 days of initiating HAART in these children. 
Time until outcomes:       90 days or 3 months. 
Time for literature:          Inception to February 2012. 
Study designs allowed:    Prospective cohort studies, retrospective cohort studies, systematic  
                                            reviews. 
Figure 2.  Eligibility criteria using “PICOTTS” framework. 
 
All 471 titles and abstracts identified through searches were reviewed for eligibility 
against our inclusion and exclusion criteria by a single reviewer (JN).  The 39 studies marked for 
possible inclusion underwent full-text review by the single reviewer to determine the final 
studies to be included in this systematic review.  All results were imported into EndNote X5® 
for tracking and management. 
 
Data Extraction and Data Management 
 Data from studies that met our inclusion criteria were abstracted into standard evidence 
tables using Microsoft Excel® software.  The evidence tables contained relevant information 
from each article, including baseline characteristics of study populations, settings, intervention, 
primary outcomes, incidence of mortality within the first 90 days of therapy, and important 
predictors of early death.  
 
Quality Assessment 
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 Articles that met our inclusion criteria were critically appraised and assigned a quality 
rating by a single reviewer (JN).  To assess internal validity, we used standardized criteria based 
on USPSTF guidelines (ratings: good, fair, poor) and the University of York Centre for Reviews 
and Dissemination.
62,63
  Four internal validity categories (quality of study design, quality of 
exposure measurement, quality of outcome assessment, and quality of statistical analysis) and 
one external validity category were used to grade risk of bias and generalizability, respectively, 
for each included study.
63
  Good quality studies require a grade of good in at least four of the five 
quality categories with no grades of poor.  Fair quality studies require a grade of good in at least 
one of the five quality categories with no grades of poor.  Poor quality studies have a fatal flaw 
(defined as a methodological shortcoming that leads to a very high risk of bias) in one or more 
categories.     
 
Grading Strength of Evidence 
 We graded the overall strength of the body of evidence (ratings: high, moderate, low, or 
insufficient) using established methodological criteria which incorporate four key domains: risk 
of bias (which includes aggregate quality), consistency, directness, and precision of the 
evidence.
64
 
 
Results 
 
Study Selection 
 The flowchart for the study selection process is presented below.  A total of 471 abstracts 
and titles were screened.  Of this total, 467 studies were obtained from MEDLINE® and an 
additional 4 studies were obtained manually from the references of relevant articles.  After initial 
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screening, 432 articles were excluded because they failed to meet the inclusion criteria.  We 
proceeded to full-text review for the remaining 39 articles for each of the key questions.  For KQ 
1 (predictors), 37of the 39 articles were excluded for failing to meet inclusion criteria—failure to 
report 90-day mortality data (n=18), failure to describe or model predictors of 90-day mortality 
(n=15), exclusion based on setting (n=2), and exclusion because children did not receive 
HAART (n=2).   For KQ 2 (causes of death), 37 of the 39 articles were excluded for failing to 
meet inclusion criteria—failure to report causes of death within the first 90 days of treatment 
(n=33), exclusion based on setting (n=2), and exclusion because children did not receive 
HAART (n=2).  Two published articles from two studies were included for KQ 1 and two 
published articles from two studies were included for KQ 2. 
 
 
25 
 
MEDLINE® search results <n=467>
Reference lists from relevant studies not 
included in MEDLINE® search <n=4>
Failed to meet criteria 
<in abstract>  <n=432>
Studies for full-text review
<n=39>
No exposure of interest 
<patients not on ART>  <n=2>
Excluded based on setting 
<high-income country>  <n=2>
KQ 1 (predictors) KQ 2 (causes of death)
Fails to report incidence of 
mortality after 90 days of ART 
<n=18>
Reports 90-day mortality data 
without description or 
modeling of predictors 
<n=15>
Studies included in 
qualitative synthesis 
<n=2>
Fails to report cause of 
death by time to mortality 
after ART initiation
<n=33>
Studies included in 
qualitative synthesis 
<n=2>
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Figure 3.  Search and selection of studies for review. 
 
 
Study Characteristics 
Key Question 1 
 Tables 1a and 1b show the study characteristics of the two studies included in the 
systematic review for KQ 1 and KQ 2, respectively.  For KQ 1, both articles were cohort studies 
conducted in resource-limited settings.  Bong et al used retrospective data from Mzuzu Central 
Hospital, north Malawi to identify the risk factors associated with mortality within 3 months of 
starting ART.
28
  Lumbiganon et al used both prospective and retrospective data from 12 sites in 
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Thailand, Malaysia, India, Indonesia, and Cambodia in order to describe the characteristics of 
those children who die within 90 days of starting HAART.
60,65
  Of the 439 children on ART in 
Bong et al, 49 children had died by the end of the study in September 2006.  Thirty-five of those 
49 deaths (71%) occurred within 3 months of initiating HAART.  Of the 1752 children on ART 
in Lumbiganon et al, 115 children had died as of March 2009.  Forty-three of those 115 deaths 
(37%) occurred within 3 months of initiating ART.  Bong et al uses multivariable Cox 
proportional hazard models in order to determine which baseline characteristics predict early 
mortality.  Unlike Bong et al, Lumbiganon et al does not create a multivariable model of 
predictors of death within 3 months of ART.  Instead, Lumbiganon et al offers a description of 
the baseline characteristics possessed by those 43 children who die within the first 3 months of 
treatment. 
Key Question 2 
 The Lumbiganon et al study was also included for KQ 2 because it reported causes of 
death within 90 days of starting HAART.  Causes of death were extracted from existing clinic 
databases or medical records.  Raguenaud et al performed a retrospective cohort study in two 
pediatric HIV clinics in Cambodia from January 2003 to December 2007.
66
  A total of 714 
children started on HAART in this study, with 20 deaths occurring in the first 90 days of 
treatment.  The study assigned causes of death for 16 of the 20 children who died within 90 days 
of initiating HAART.  The most likely attributable cause of death of each patient was assigned 
based on the last diagnosis available in patient records. 
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KEY QUESTION 1         
Study author 
(year) 
location 
 
Study characteristics, 
sample size,  
and sample demographics 
 
Measurement of 
risk factors 
 
Assessment of 
treatment outcomes and 
risk factors associated 
with early death  
Comments 
 
 
Bong et al. (2007) 
Mzuzu Central 
Hospital, 
north Malawi 
 
 
 
 
 
 
 
 
 
 
 
 
 
Retrospective cohort study 
July 2004-September 2006 
439 children on ART; 50% 
male; median age of 6 
years; 37 children (8%) in 
highest risk age group (<18 
months) therefore a 
survivor bias is possible 
that may lead to an 
underestimate of mortality. 
 
 
 
 
 
 
 
 
 
 
Baseline clinical 
assessment included 
nutritional 
evaluation and 
measurement of 
CD4 count and 
percentage.  Seven 
clinical and 
demographic factors 
were included in 
initial univariate 
analysis to build 
multivariate model.  
Characteristics 
monitored and 
recorded on 
HAART treatment 
master cards and the 
HAART register.  
Does not describe at 
what time 
laboratory values 
were measured with 
respect to the date 
of CD4 initiation. 
 
 
35 children (71%) died in 
the first 3 months on 
HAART.  WHO clinical 
stage 4 (HR=5.5), severe 
wasting (HR=2.9), and 
CD4 cell count (HR=2.1) 
significantly associated 
with death within 3 
months in multivariable 
Cox proportional hazard 
model. 
 
 
 
 
 
 
 
 
6-week run-in period 
requiring 95% drug 
adherence improves 
efficacy but limits 
effectiveness. 
Multivariate model 
built using 
independent variables 
that were significant at 
the P<0.05 level in 
univariate analysis. 
Guardians received 
pre-HAART 
counseling and 
education about how 
to administer split 
tablets. 
 
 
 
 
 
Lumbiganon et al. 
(2011) 
Multicenter study 
(Thailand,  
Malaysia, India,  
Indonesia, 
Cambodia) 
 
 
 
 
 
 
 
 
 
Prospective and 
retrospective cohort study 
1994-March 2009 
(prospective data since 
December 2007)  
1752 children on HAART; 
1480 children (84%) on 
combined ART; 272 
children (16%) on mono- or 
dual-NRTI; median age of 
6.5 years; 315 children 
(18%) <18 months. 
 
 
 
 
 
 
Frequency of clinic 
visits and laboratory 
testing depends on 
the clinic's standard 
practice patterns.  
Quality assurance 
measures to check 
data against the 
medical record for 
accuracy.  Seven 
baseline 
characteristics were 
included in the 
descriptive 
statistics.  
Laboratory values 
from within 3 
months before (all 
tests) and 1 month 
after HAART 
43 children (37.3%) died 
in the first 3 months on 
HAART.  Provides 
descriptive statistics of 
characteristics of the 43 
children who died within 
90 days of starting ART.  
Of the 43 children, 25 
children (58.1%) were 
ages 5-12; 19 children 
(44.2%) had baseline 
CD4%<5%; 23 children 
(53.5%) had WHO 
clinical stage 4 disease; 
median weight-for-age z-
score was -5.1. 
 
 
 
 
Largest analysis of 
survival and mortality 
in HIV-infected 
children across Asia. 
Multivariable model 
only measures risk 
factors associated with 
increased hazard of 
overall mortality and 
not 90-day mortality.  
 
 
 
 
 
 
 
28 
 
initiation (except for 
CD4) were used as 
baseline values. 
Table 1a.  Study characteristics (KQ 1). 
 
KEY QUESTION 2         
Study author (year) 
location 
 
Study 
characteristics, 
sample size,  
and sample 
demographics 
Cause of death 
reporting by time 
to mortality 
 
Assessment of 
outcomes 
 
Comments 
 
 
Raguenaud et al. 
(2009) 
Siem Reap province 
and Takeo province, 
Cambodia 
 
 
 
 
 
 
 
 
Retrospective cohort 
study conducted in 
the pediatric HIV 
clinics of the Angkor 
Hospital for Children 
in Siem Reap 
province and in 
Donkeo Referral 
Hospital in Takeo 
province.  All 
children <15 years 
with confirmed HIV-
positive status were 
included from 
January 2003-
December 2007.  
1168 HIV-positive 
children enrolled. 
714 children started 
HAART. 
Twenty children 
died within 90 
days of initiating 
HAART.  Among 
children on 
HAART, 
tuberculosis (7 
children, 44%) and 
respiratory tract 
infections (4 
children, 25%) 
were the most 
common causes of 
death within the 
first 90 days. 
 
 
The most likely 
attributable cause 
of death of each 
patient was 
assigned based on 
the last diagnosis 
available in patient 
records. 
 
 
 
 
 
Majority of 
the population 
lives in rural 
areas where 
socioeconomic 
status is very 
low.  
Virological 
testing for 
HIV diagnosis 
in children 
younger than 
18 months of 
age was made 
available 
during the 
year 2006. 
 
 
 
 
 
 
Lumbiganon et al. 
(2011) 
Multicenter study 
(Thailand,  
Malaysia, India,  
Indonesia, 
Cambodia) 
 
 
 
 
 
 
 
 
 
 
 
(As in Table 1a) 
Prospective and 
retrospective cohort 
study 1994-March 
2009 (prospective 
data since December 
2007)  
1752 children on 
HAART; 1480 
children (84%) on 
combined ART; 272 
children (16%) on 
mono- or dual-NRTI; 
median age of 6.5 
years; 315 children 
(18%) <18 months. 
 
 
 
Provides a table 
reporting causes of 
death by time since 
HAART initiation.  
Among the 43 
children who died 
within 3 months of 
starting HAART, 
15 children (35%) 
died of 
pneumonia/sepsis, 
12 (28%) died of 
other opportunistic 
infections, 7 (16%) 
died of AIDS, 2 
(5%) died of 
serious adverse 
events, 2 (5%) died 
of other causes, 
and 5 (12%) died 
of unknown 
 
 
 
Causes of death 
were extracted 
from existing clinic 
databases or 
medical records.  
Individual clinic 
sites provided 
cause of death data 
for those who died 
and those who were 
LTFU during the 
retrospective period 
although cause of 
death data were not 
always available. 
 
 
 
Note that 1752 
children 
initiated on 
some level of 
HAART, with 
1480 (84%) on 
triple therapy.  
Does not 
report cause of 
death by 
HAART 
regimen.  
Regimens 
vary by clinic 
site.  Unclear 
how many 
deaths were 
extracted from 
retrospective 
data versus 
prospective 
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causes.  One of the 
deaths due to 
pneumonia/sepsis 
was suspected 
IRIS. 
 
 
 
data. 
 
 
 
Table 1b  Study characteristics (KQ 2). 
 
Risk of Bias within Studies 
Key Question 1 
 Tables 2a and 2b display quality ratings evaluating the internal validity and external 
validity of the studies included in the systematic review for KQ 1 and KQ 2, respectively.  For 
KQ 1, both studies received an overall grade of poor.  In general, pediatric HIV cohort studies in 
resource-poor settings have been limited by small sample sizes, significant loss to follow-up, and 
limited diagnostic tools.
2,23
  In Bong et al, nearly 9 percent of patients were lost to follow-up and 
an additional 10 percent transferred care.  The article does not offer any reassurance that those 
patients lost to follow-up are not systematically different from those patients who remained in 
the study, thereby introducing selection bias and limiting internal validity.    
Additionally, Bong et al calculates adjusted hazard ratios in order to measure the 
association between baseline risk factors and mortality within three months of initiating 
HAART.  But over such a short period of time, risk ratios, rather than hazard ratios, may be more 
appropriate.  Although there are several methodological problems with hazard ratios, in general, 
most of these problems would be mitigated over a short period of time like 90 days.
67
  The three 
month hazard ratio, a period-specific hazard ratio, is the weighted average of even smaller 
period-specific hazard ratios.  Three months is a short enough period of time that the three month 
hazard ratio should capture the potentially time-varying magnitude of an early mortality effect 
that would not be captured in an average hazard ratio calculated over years of follow-up.  
However, a period-specific hazard ratio, as used by Bong et al, is susceptible to built-in selection 
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bias.  The hazard is the instantaneous risk evaluated among those who have not yet had the event 
in question.  For example, at day 89, the hazard ratio measures the instantaneous risk of death 
given a certain independent variable among those children who have not yet died.  But the 
population at day 89 is quite different than the population at day 1.  In particular, the population 
at day 89 has fewer children at the very high risk of death experienced on day 1.  Compared to 
the baseline population, the population at day 89 suffers from selection bias.  Therefore, the 
period-specific hazard ratio may still be time-varying because of built-in selection bias.  A useful 
clinical prediction tool predicts early mortality given a set of baseline characteristics at a specific 
point in time.  Although certainly difficult, one alternative method that overcomes these 
problems would be appropriately adjusted survival curves.
67,68
  Overall, the Bong et al study is 
poor because it suffers from loss to follow-up and a high risk of selection bias and has only fair 
generalizability given a strict run-in period excluding less compliant patients.   
 Lumbiganon et al also suffers from significant loss to follow-up (8.8%) without 
describing the characteristics of those children who lack primary outcome data.  The study is a 
combination of retrospective and prospective cohort data across 12 sites in 5 countries.  Clinics 
enrolling patients before the start of the prospective study in December 2007 did not share a 
common protocol and therefore retrospective data cannot be standardized, making comparison 
difficult.  In addition, Lumbiganon et al only provides descriptive statistics about the children 
who died within the first 90 days of initiating HAART.  The multivariable model measures risk 
factors associated with increased hazard of overall mortality but not the period-specific 90-day 
mortality that is most relevant when predicting future death based on time-varying factors.  The 
study does have fair external validity because the study population is sufficiently heterogeneous 
with respect to demographics, health status, education, and social factors.  However, the overall 
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grade for this study is poor because of its reliance on retrospective data that has not been 
standardized across study sites, significant loss to follow-up making it susceptible to selection 
bias, and its failure to analyze period-specific mortality in the multivariable model. 
Key Question 2 
 In Lumbiganon et al, the authors note that because the data were both retrospectively and 
prospectively collected, specific causes of death and outcomes of children LTFU were not fully 
ascertainable.  At least three children had suspected IRIS; however, the impact of immune 
reconstitution on mortality was unclear.  In addition, the study attributes 7 of the 43 early deaths 
to AIDS without explaining how death due to AIDS differs from death due to opportunistic 
infection (12 deaths) or pneumonia/sepsis (15 deaths).  A total of 154 children (8.8%) were 
LTFU, raising the possibility that some deaths may have been misclassified as LTFU. 
 In Raguenaud et al, not all causes of death were reliably ascertained as 4 out of the 20 
early deaths did not have a known cause.  Nevertheless, the authors state that the level of error in 
attributing cause of death was limited because the study occurred in a large referral center with 
medical doctors performing all consultations.  The study used active tracing to limit LTFU 
(1.8%), thereby reducing the probability of misclassifying some deaths as LTFU. 
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KEY QUESTION 1           
Study 
author 
(year) 
Quality of study 
design  
(reporting, loss 
to follow-up) 
Quality of risk 
factor  
measurement 
Quality of 
outcome 
measurement 
Quality of 
statistical 
analysis 
Overall external 
validity 
Overall 
grade 
Bong et al. 
(2007) 
 
 
 
 
 
 
 
 
 
 
 
Poor - 28 
children (8.6%) 
were lost to 
follow-up despite 
active tracing; 46 
children (10.4%) 
permanently 
transferred to 
another facility.  
Significant 
proportion of 
those lost to 
follow-up had 
likely died 
resulting in 
underestimation 
of mortality 
rates. 
 
Fair - WHO 
clinical staging 
based on 
bacterial 
infections 
limited by lack 
of sophisticated 
lab facilities so 
incorrect 
clinical staging 
possible. 
 
 
 
 
 
Fair - 
Characteristics,  
WHO clinical 
stage, 
compliance with 
visits,  
drug adherence, 
and outcomes of 
children on 
HAART were 
recorded from 
the HAART 
master card and 
HAART register. 
 
 
 
 
Fair - Does not 
describe  
whether 
proportional  
hazards 
assumption was  
tested.  Given 
short period  
of time, RRs 
instead of HRs  
may be more 
interpretable. 
 
 
 
 
 
Fair - Strict run-in 
period and 
exclusion of  
transfer patients 
from other 
HAART  
facilities limits 
external validity. 
Split-tablet adult 
fixed-dose 
combination 
HAART is same 
regimen used 
throughout 
Malawi so results 
may be 
generalizable to 
all HAART 
facilities in the 
country. 
 
 
Poor 
 
 
 
 
 
 
 
 
 
 
 
Lumbiganon 
et al. (2011) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Poor - 154 
children (8.8%) 
were lost to 
follow-up. 
Significant 
heterogeneity in 
practice and 
follow-up times 
is possible across 
12 sites in 5 
countries. 
 
 
 
 
 
 
 
 
Poor - Absent 
data on 
adherence and 
viral load.  
Reliability of 
retrospective 
data from 
medical record 
extraction is 
limited due to 
the differing 
levels of 
documentation 
requirements 
across sites. 
59% of first 
clinic visits 
lack CD4 cell 
percent and 
44% lack 
clinical 
staging. 
 
 
 
Fair - 
Retrospective  
data have not 
been  
standardized and  
clinics enrolling  
patients before  
initiation of  
prospective study  
lacked a common  
protocol.  
 
 
 
 
 
 
 
 
Fair - Descriptive 
statistics about 
children who 
died within 90 
days of initiating 
HAART fails to 
report which 
HAART regimen 
was being used. 
"Intent to 
continue 
treatment" 
approach did not 
take into account 
changes to 
treatment or 
WHO guidelines.  
Multivariable 
model estimates 
the hazard of 
overall mortality 
after initiating 
HAART based 
on time-varying 
baseline 
characteristics. 
 
Fair - Study  
population is  
heterogeneous  
with respect to  
demographics,  
health status,  
education, and  
social factors  
although  
participating sites  
are mainly  
university-based  
clinics and major  
referral centers. 
 
 
 
 
 
 
 
Poor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2a.  Quality ratings (KQ 1). 
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KEY QUESTION 2 
 
          
Study author 
(year) 
location 
Quality of 
study design  
(reporting, 
loss to follow-
up) 
Quality of 
exposure 
measurement 
Quality of 
outcome 
measurement 
Quality of 
statistical 
analysis 
Overall external 
validity 
Overall 
grade 
 
Raguenaud et al. 
(2009) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fair - Large 
cohort of 
children on 
HAART.  
LTFU was low 
(1.8%) for 
children on 
HAART.  For 
children who 
were not 
treated, LTFU 
was higher 
(22%) so there 
were likely 
more 
unreported 
deaths in the 
untreated 
group.  Used 
an active 
tracing system 
for children on 
HAART who 
failed to attend 
a clinic 
appointment in 
order to reduce 
LTFU.    
 
 
    
Not applicable 
for KQ 2 
although no 
data on 
adherence.  
Patients and 
caregivers 
received at 
least three 
HAART-
preparation 
counseling 
sessions before 
starting 
treatment to 
maximize 
adherence. 
 
 
 
 
 
Fair - Not all 
causes of death 
were reliably 
ascertained.  
Nevertheless, 
given that both 
HIV programs 
were situated 
within provincial 
referral hospitals 
and that medical 
doctors performed 
all consultations, 
the authors 
believe that the 
level of error in 
attributing cause 
of death was 
limited.  
 
 
 
 
Not applicable for 
KQ 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fair – 
Generalizable to 
other rural 
populations with 
low 
socioeconomic 
status. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Poor 
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Lumbiganon et al. 
(2011) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fair – Does not 
report period-
specific LTFU 
rates.  Overall, 
154 children 
(8.8%) were 
LTFU.  
Comparing the 
high 3-month 
mortality rate 
(10.2 per 100 
child-years) to 
a 3-month 
LTFU rate 
would have 
allowed 
authors to 
hypothesize 
whether some 
patients who 
had died were 
misclassified 
as LTFU 
during this 
high risk time 
period.  A 
comparatively 
lower 3-month 
LTFU rate 
would give 
confidence that 
children LTFU 
were correctly 
classified and 
had not 
actually died. 
 
 
 
 
Fair – KQ 2 
does not 
necessarily 
require an 
exposure 
measurement 
although 
providing 
adherence data 
would have 
increased 
reliability that 
children were 
actually taking 
HAART when 
they died.  No 
information 
about the 
specific 
HAART 
regimen for 
each death.  
 
 
 
 
 
 
 
 
 
 
Fair – Authors 
note that because 
data were both 
retrospectively 
and prospectively 
collected, specific 
causes of death 
and outcomes of 
children LTFU 
were not fully 
ascertainable.  
Authors also state 
that although 
there were at least 
3 children with 
suspected IRIS, 
they were unable 
to assess the 
impact of immune 
reconstitution on 
mortality.  
Unclear what 
authors mean by 
death due to 
AIDS when other 
causes of death 
include 
opportunistic 
infections and 
pneumonia/sepsis.  
Retrospective 
data were not 
standardized 
across clinic sites.  
Outcomes may 
have been 
verified 
differently at 
different clinics 
or at different 
times within the 
same clinic. 
Not applicable for 
KQ 2.  The study 
reports causes of 
death within the 
first 90 days of 
HAART initiation 
and therefore met 
the inclusion 
criteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fair – 
Participating 
study sites are 
mainly 
university-based 
clinics and major 
referral centers 
so the extent to 
which these 
findings can be 
generalized to 
more primary-
care-focused 
clinics and rural 
clinics is unclear. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Poor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2b.  Quality ratings (KQ 2). 
 
Synthesis of Results 
Key Question 1 
 For KQ 1, Bong et al found that WHO clinical stage 4 disease, severe wasting (defined as 
weight for height <70%), and severe immunodeficiency (defined as baseline CD4 count below 
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age threshold) were significantly associated with early mortality by 3 months after starting 
treatment.  Lumbiganon et al observed that among the 43 children who died in the first 3 months 
of ART (37.3% of all deaths), 25 children (58.1%) were ages 5-12, 19 children (44.2%) had 
baseline CD4%<5%, 23 children (53.5%) had WHO clinical stage 4 disease, and the median 
weight-for-age z-score was -5.1.  Although Lumbiganon et al does not calculate the period-
specific risk of death in a multivariable model as in Bong et al, the results of the study are 
consistent with the findings in Bong et al.  Overall, the high early mortality and identified risk 
factors in the children in both studies are similar to those found in adults and to those found in 
pediatric studies measuring predictors of overall mortality.
3,8,23,28-34
  
Key Question 2 
 In Lumbiganon et al, the leading causes of mortality during the first three months of 
HAART were tuberculosis (7 children, 44%) and respiratory tract infections (4 children, 25%).  
There were three patients with suspected IRIS in Lumbiganon et al; however, the impact of 
immune reconstitution on mortality in these patients was unclear. Among the 43 children who 
died within three months of starting HAART in Raguenaud et al, the most common causes of 
death were pneumonia/sepsis (15 children, 35%), opportunistic infections (12 children, 28%), 
and AIDS (7 children, 16%).   
 
Overall Grade of Evidence 
Key Question 1  
The overall grade of the evidence describing risk factors associated with early mortality 
is low.  Conducting observational pediatric HIV studies in low-income countries without 
significant risk of bias is impossible.  There are many challenges to developing pediatric 
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HAART programs outside well-equipped settings that make studying pediatric cohorts in these 
settings extremely difficult.  It is also likely that genetic, dietary, and social differences among 
patient populations, as well as differences in general health care access, local medical practices, 
and concurrent medicines and illnesses, influence clinical outcomes in resource-poor settings.
2
  
Nevertheless, the two studies are consistent in terms of which baseline characteristics predict 
early mortality in HAART-naive, HIV-infected children beginning treatment.  The small sample 
size in Bong et al resulted in wide confidence intervals around the adjusted HR point estimates 
which detract from precision.  One similar pediatric HIV cohort study excluded from the 
systematic review reported 99 percent of deaths occurring during the first 90 days after HAART 
initiation with deceased children being younger, more malnourished, and presenting with lower 
CD4 counts.
32
  The consistency between these three studies and other studies of predictors of 
overall mortality after HAART initiation in children should give us confidence in the reliability 
of these findings.  Overall, there is weak, but growing, evidence indicating that malnutrition, 
WHO clinical stage 4 disease severity, and low CD4 count are the most important predictors of 
early death in children initiating HAART and therefore should be used to identify those children 
most in need of increased medical attention. 
Key Question 2 
 The overall grade of the evidence is insufficient to draw conclusions about the causes of 
early death in children initiating HAART.  As HAART becomes much more widely available in 
resource-limited settings, IRIS has emerged as an important complication of HAART.
49
  Without 
improved cause-of-death reporting, the contribution of IRIS to early mortality in children 
initiating HAART will remain unknown. 
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